Advances in the development of tau PET radiotracers and their clinical applications

Ageing Research Reviews
Nobuyuki OkamuraYukitsuka Kudo

Abstract

Alzheimer's disease and other neurodegenerative dementias belong to the family of tauopathies. These diseases are characterized by the deposition of insoluble tau aggregates possessing an enriched β-sheet structure. In vivo imaging of the tau deposits by positron emission tomography (PET) will facilitate the early and accurate diagnosis of these diseases, tracking of disease progression, assessment of disease severity, and prediction of disease prognosis. Furthermore, this technology is expected to play a vital role in the monitoring of treatment outcomes and in the selection of patients for the therapeutic trials of anti-dementia drugs. Recently, several tau PET tracers have been successfully developed and demonstrated as having high binding affinity and selectivity to tau protein deposits. Recent clinical studies using these tracers have demonstrated significant tracer retention in sites susceptible to tau deposition in Alzheimer's disease, as well as correlations with the disease severity and cognitive impairment in cases with dementia. These tracers, thus, have the potential to effectively diagnose the tauopathies. Further longitudinal assessment will clarify the effect of the tau deposition on the neurodegenerative process...Continue Reading

References

Jan 1, 1991·Acta Neuropathologica·H Braak, E Braak
Nov 1, 1989·Neurobiology of Aging·W BondareffD L Hauser
Aug 25, 2001·Annual Review of Neuroscience·V M LeeJ Q Trojanowski
Jan 16, 2002·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Kooresh Shoghi-JadidJorge R Barrio
May 16, 2007·Neurology·C C RoweV L Villemagne
Apr 21, 2009·Neurobiology of Aging·Joseph L PriceJohn C Morris
May 18, 2010·Neurobiology of Aging·Christopher C RoweVictor L Villemagne
Jul 2, 2011·Journal of Molecular Neuroscience : MN·Dennis W DicksonKeith A Josephs
Apr 6, 2013·Nature Reviews. Neurology·Steven T DeKoskySam Gandy
Jul 17, 2013·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Nobuyuki OkamuraYukitsuka Kudo
Jul 23, 2013·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Ryuichi HaradaYukitsuka Kudo
Nov 2, 2013·NeuroImage. Clinical·Rik VandenbergheGaël Chételat
Feb 28, 2014·Alzheimer's Research & Therapy·Michelle T Fodero-TavolettiVictor L Villemagne
Mar 22, 2014·Science Translational Medicine·Reisa A SperlingPaul Aisen
Apr 1, 2014·Brain : a Journal of Neurology·Nobuyuki OkamuraVictor L Villemagne
Jun 14, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Victor L Villemagne, Nobuyuki Okamura
Jun 26, 2014·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Hiroki HashimotoMing-Rong Zhang
Aug 16, 2014·Neuropathology : Official Journal of the Japanese Society of Neuropathology·Mari Yoshida
Sep 23, 2014·Current Neurology and Neuroscience Reports·Nobuyuki OkamuraYukitsuka Kudo
Dec 3, 2014·Annals of Neurology·Rik OssenkoppeleGil D Rabinovici
Dec 17, 2014·Lancet Neurology·Victor L VillemagneChristopher C Rowe
Jan 13, 2015·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Yi LiMony J de Leon
Jul 18, 2015·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Yasuyuki KimuraMakoto Higuchi

❮ Previous
Next ❯

Citations

Oct 26, 2016·Brain Research Bulletin·Thomas ArendtMax Holzer
Sep 22, 2016·Critical Reviews in Biochemistry and Molecular Biology·Julia E GersonRakez Kayed
Mar 24, 2017·European Journal of Nuclear Medicine and Molecular Imaging·Nare TorosyanUNKNOWN Alzheimer’sDisease Neuroimaging Initiative
Oct 28, 2017·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Piotr LewczukUNKNOWN Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato
Oct 27, 2017·F1000Research·Leonardo IaccarinoDaniela Perani
May 19, 2019·Pharmaceutics·Ana Castro-BaladoAnxo Fernández-Ferreiro
Jun 25, 2019·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Daniela PeraniUNKNOWN IMBI Project
Jul 16, 2020·Journal of Personalized Medicine·Chiara VillaRomina Combi
Jul 25, 2017·Neurology and Therapy·Lih-Fen LueDouglas G Walker
Jan 6, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Liana G ApostolovaDaniel H Silverman
Nov 18, 2016·Nature Reviews. Disease Primers·Kaj BlennowHenrik Zetterberg
Nov 15, 2017·Current Treatment Options in Neurology·Nasim Sheikh-BahaeiAimee L Pierce
Jul 19, 2017·JAD Reports·Nasim Sheikh-BahaeiJonathan Harvey Gillard
Jan 22, 2020·European Journal of Nuclear Medicine and Molecular Imaging·Jenny CeccariniKoen Van Laere
Jun 4, 2018·Bioorganic & Medicinal Chemistry Letters·Mingzhang GaoQi-Huang Zheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.